- US12590162utility2026Cancer Treatment0 cites
- US12582640utility2026Treatment of Lower Respiratory Tract Infection with Tradipitant0 cites
- US12544367utility2026Method of Treatment of Schizophrenia0 cites
- US12527772utility2026Pharmaceutical Combination Comprising Ponesimod0 cites
- US12502379utility2025Ponesimod for Avoiding Worsening of Fatigue-related Symptoms in Multiple Sclerosis Patients0 cites
- US12478619utility2025Method of Treatment with Milsaperidone0 cites
- US12447141utility2025Liquid Tasimelteon Formulations and Methods of Use Thereof0 cites
- US12440470utility2025Liquid Tasimelteon Formulations and Methods of Use Thereof0 cites
- US12427132utility2025Method of Improving Sleep0 cites
- US12419869utility2025Methods of Treating Multiple Sclerosis0 cites
- US12409167utility2025Pharmaceutical Combination Comprising a Selective S1P 1 Receptor Agonist0 cites
- US12403134utility2025Method for Improving or Enhancing Cognition0 cites
- US12357616utility2025Methods of Treating Multiple Sclerosis0 cites
- US12336980utility2025Dosing Regimen for a Selective S1P1 Receptor Agonist0 cites
- US12318375utility2025Method of Treatment with Tradipitant0 cites
- US12304896utility2025Highly Purified Pharmaceutical Grade Tasimelteon0 cites
- US12201583utility2025Pharmaceutical Dosage System0 cites
- US12201604utility2025Treatment of Circadian Rhythm Disorders0 cites
- US12146185utility2024Genetic Markers for Enhancing Efficacy of Antipsychotic Treatment with Iloperidone0 cites
- US12049457utility2024Highly Purified Pharmaceutical Grade Tasimelteon0 cites
Page 1 of 2Next →